Species‐level, metagenomic and proteomic analysis of microbe‐immune interactions in severe asthma
Year: 2024
Type: article
Study design: Observational Study
Abstract: BACKGROUND: The airway microbiome in severe asthma has not been characterised at species-level by metagenomic sequencing, nor have the relationships between specific species and mucosal immune responses in 'type-2 low', neutrophilic asthma been defined. We performed an integrated species-level metagenomic data with inflammatory mediators to characterise prevalence of dominant potentially pathogenic organisms and host immune responses. METHODS: Sputum and nasal lavage samples were analysed using long-read metagenomic sequencing with Nanopore and qPCR in two cross-sectional adult severe asthma cohorts, Wessex (n = 66) and Oxford (n = 30). We integrated species-level data with clinical parameters and 39 selected airway proteins measured by immunoassay and O-link. RESULTS: The sputum microbiome in health and mild asthma displayed comparable microbial diversity. By contrast, 23% (19/81) of severe asthma microbiomes were dominated by a single respiratory pathogen, namely H. influenzae (n = 10), M. catarrhalis (n = 4), S. pneumoniae (n = 4) and P. aeruginosa (n = 1). Neutrophilic asthma was associated with H. influenzae, M. catarrhalis, S. pneumoniae and T. whipplei with elevated type-1 cytokines and proteases; eosinophilic asthma with higher M. catarrhalis, but lower H. influenzae, and S. pneumoniae abundance. H. influenzae load correlated with Eosinophil Cationic Protein, elastase and IL-10. R. mucilaginosa associated positively with IL-6 and negatively with FGF. Bayesian network analysis also revealed close and distinct relationships of H. influenzae and M. catarrhalis with type-1 airway inflammation. The microbiomes and cytokine milieu were distinct between upper and lower airways. CONCLUSIONS: This species-level integrated analysis reveals central, but distinct associations between potentially pathogenic bacteria and airways inflammation in severe asthma.
Source: Allergy
DOI: 10.1111/all.16269
Institutions: John Radcliffe Hospital, National Institute for Health and Care Research, University of Oxford, NIHR Oxford Biomedical Research Centre, University of Padua, NIHR Southampton Respiratory Biomedical Research Unit, University of Southampton, Portsmouth Hospitals NHS Trust, Medawar Building for Pathogen Research
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,150
Funders: Pfizer, AstraZeneca, Sanofi, Teva Pharmaceutical Industries, Wellcome Trust, UK Research and Innovation, National Institute for Health and Care Research, Department of Health and Social Care, University of Oxford, National Institute for Health Research Southampton Biomedical Research Centre, Sanofi Genzyme, Medical Research Council, NIHR Oxford Biomedical Research Centre
OpenAlex ID: W4401495919
